Analyst Expectations For Penumbra's Future
Benzinga Insights 9 months ago
Analyst Ratings
Analysts' ratings for Penumbra (NYSE:PEN) over the last quarter vary from bullish to bearish, as provided by 14 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 1 | 5 | 0 | 0 |
| Last 30D | 0 | 0 | 3 | 0 | 0 |
| 1M Ago | 4 | 1 | 1 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 3 | 0 | 1 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $353.86, a high estimate of $388.00, and a low estimate of $275.00. Marking an increase of 10.32%, the current average surpasses the previous average price target of $320.75.
Analyzing Analyst Ratings: A Detailed Breakdown
The analysis of recent analyst actions sheds light on the perception of Penumbra by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Rescott | Baird | Raises | Neutral | $374.00 | $345.00 |
| Ryan Zimmerman | BTIG | Announces | Neutral | $349.00 | - |
| Richard Newitter | Truist Securities | Raises | Hold | $374.00 | $370.00 |
| Larry Biegelsen | Wells Fargo | Announces | Equal-Weight | $374.00 | - |
| Travis Steed | B of A Securities | Raises | Buy | $370.00 | $320.00 |
| Richard Newitter | Truist Securities | Raises | Buy | $370.00 | $312.00 |
| Robert Marcus | JP Morgan | Raises | Overweight | $370.00 | $275.00 |
| Jason Mills | Canaccord Genuity | Raises | Buy | $359.00 | $355.00 |
| Mike Matson | Needham | Raises | Buy | $388.00 | $326.00 |
| Joanne Wuensch | Citigroup | Raises | Buy | $350.00 | $285.00 |
| Robert Marcus | JP Morgan | Raises | Neutral | $275.00 | $265.00 |
| Jason Mills | Canaccord Genuity | Raises | Buy | $355.00 | $350.00 |
| Mike Matson | Needham | Maintains | Buy | $326.00 | $326.00 |
| Ryan Zimmerman | BTIG | Maintains | Buy | $320.00 | $320.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Penumbra. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Penumbra compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Penumbra's stock. This analysis reveals shifts in analysts' expectations over time.
For valuable insights into Penumbra's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Penumbra analyst ratings.
Discovering Penumbra: A Closer Look
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
Penumbra's Economic Impact: An Analysis
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, Penumbra showcased positive performance, achieving a revenue growth rate of 17.82% as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Penumbra's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 12.93% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Penumbra's ROE stands out, surpassing industry averages. With an impressive ROE of 3.46%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Penumbra's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.68%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.16, Penumbra adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Significance of Analyst Ratings Explained
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.